%0 Journal Article
%A Galinovic, Ivana
%A Fiebach, Jochen B
%A Boutitie, Florent
%A Cheng, Bastian
%A Cho, Tae-Hee
%A Ebinger, Martin
%A Endres, Matthias
%A Enzinger, Christian
%A Fiehler, Jens
%A Ford, Ian
%A Gregori, Johannes
%A Günther, Matthias
%A Lemmens, Robin
%A Muir, Keith W
%A Nighoghossian, N.
%A Roy, Pascal
%A Simonsen, Claus Z
%A Thijs, Vincent N
%A Wouters, Anke
%A Gerloff, Christian
%A Thomalla, Götz
%A Pedraza, Salvador
%T Effect of IV Thrombolysis With Alteplase in Patients With Vessel Occlusion in the WAKE-UP Trial.
%J Neurology
%V 104
%N 2
%@ 0028-3878
%C [Erscheinungsort nicht ermittelbar]
%I Ovid
%M DZNE-2025-00025
%P e209871
%D 2025
%X Data from randomized trials on the treatment effect of pure thrombolysis in patients with vessel occlusion are lacking. We examined data from a corresponding subsample of patients from the multicenter, randomized, placebo-controlled WAKE-UP trial to determine whether MRI-guided IV thrombolysis with alteplase in unknown-onset ischemic stroke benefits patients presenting with vessel occlusion.Patients with an acute ischemic lesion visible on MRI diffusion-weighted imaging but no marked parenchymal hyperintensity on fluid-attenuated inversion recovery images were randomized to treatment with IV alteplase or placebo. The primary end point was a favorable outcome defined by a modified Rankin Scale score of 0-1 at 90 days after stroke. We investigated the interaction between vessel status and treatment effect using an unconditional logistic regression model. Treatment effects (adjusted odds ratio [aOR]) and their 95
%K Humans
%K Tissue Plasminogen Activator: administration & dosage
%K Tissue Plasminogen Activator: therapeutic use
%K Female
%K Male
%K Middle Aged
%K Fibrinolytic Agents: administration & dosage
%K Fibrinolytic Agents: therapeutic use
%K Aged
%K Ischemic Stroke: drug therapy
%K Ischemic Stroke: diagnostic imaging
%K Thrombolytic Therapy: methods
%K Treatment Outcome
%K Diffusion Magnetic Resonance Imaging
%K Double-Blind Method
%K Tissue Plasminogen Activator (NLM Chemicals)
%K Fibrinolytic Agents (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39705631
%2 pmc:PMC11666272
%R 10.1212/WNL.0000000000209871
%U https://pub.dzne.de/record/274044